25-28 November 2025

Crocus Expo, Pavilion 2, Eurasia

Antiseptic And Disinfectant Market: Price Increase With Stable Consumption

Published on: May 29, 2025

Reading Time: 5 min

According to RNC Pharma analysts, in January-April 2025, retail sales of antiseptic and disinfectant products (excluding alcohol-containing products) in Russia reached 6.1 billion rubles (including VAT)


This figure exceeds the results of the same period in 2024 by 9.2%.

 

Key trends:

 

// The volume of consumption in physical terms remained practically unchanged (-0.1%)
// The average price for this category of drugs increased by 10% year-on-year


The observed dynamics indicate the influence of inflationary processes on the market: the growth in turnover is due exclusively to rising prices, and not to an increase in demand.

 

According to the results of 2024, the volume of antiseptic sales in retail amounted to 204.5 million packages worth 17.9 billion rubles. In physical terms, the growth was minimal (+0.7%), while in monetary terms it was +10.7%. For comparison: in 2023, the antiseptic market decreased by 1.2% in monetary terms and by 4.2% in packages compared to 2022.

 

In January-April 2025, about 250 antiseptic and disinfectant products (based on 30 international nonproprietary names - INN) were presented in retail. Chlorhexidine and Hydrogen Peroxide account for 55% of sales in physical terms.

 

The leaders in revenue were products with the INN benzyldimethyl-myristoylamino-propylammonium (more than 34% of the monetary volume). The key drug was Miramistin from the Russian corporation Infamed. In addition to this brand, six brands from other manufacturers are also present in retail. However, sales of Miramistin itself remained almost unchanged: +1.7% in rubles and +0.02% in packages.

 

Furacilin (produced by more than 20 companies, including OAO Avexima) took second place in terms of sales. The brand showed growth of +13.4% in rubles, despite a 4.3% decrease in packages. Chlorhexidine (also produced by about 20 companies) followed, moving up from fifth to third place. The product demonstrated record growth: +34.6% in monetary terms and +9.3% in kind.

 

The most significant growth in the top 10 was shown by Teymurova Pasta (produced by four companies): +41% in rubles, although physical sales decreased by 4.5%.

 

Earlier, RNC Pharma reported that the volume of drug sales on the Russian retail market for January-February 2025 amounted to 1.64 trillion rubles (in retail prices, including VAT). A total of 4.92 billion packages were sold during the specified period.

 

* Source : GxP News.

 

Visit the Pharmtech & Ingredients 2025 exhibition stand and business program events on November 25–28 at the Crocus Expo IEC for free by receiving an electronic ticket using the promo code pharmtech